-+ 0.00%
-+ 0.00%
-+ 0.00%

Shandong Boan Biotech expects H1 net loss RMB 79 million-RMB 89 million

PUBT·08/14/2026 14:16:44
Listen to the news
Shandong Boan Biotech expects H1 net loss RMB 79 million-RMB 89 million
  • Shandong Boan Biotechnology guided for a net loss attributable to owners of RMB 79-89 million for H1 2026.
  • That compares with a net profit attributable to owners of about RMB 21 million in H1 2025.
  • Profit swing driven by higher R&D spending tied to an accelerated innovation push, with more candidates entering clinical trials.
  • Interim results for the period are scheduled for release on Aug. 27, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260814-12285693), on August 14, 2026, and is solely responsible for the information contained therein.